AO 139 (Rev. 198/10) REPORT ON THE Mail Stop 8 10 Director of the U.S. Patent and Trademark Office FILING OR DETERMINATION OF AN P.O. Box 1450 ACTION REGARDING A PATENT OR Alexandria, VA 22313-1450 TRADEMARK to Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1110 you are hereby advised that a court action has been For the District of Delaware filed in the U.S. District Court on the following Trademarks or ☑ Patents (☐ the patent action involves 35 U.S.C. § 192.). U.S. DISTRICT COURT DOCKET NO. DATE FILED 4/21/2014 For the District of Delaware PLAINTIFF DEFENDANT FOREST LABORATORIES, INC., et al AMNEAL PHARMACEUTICALS LLC. et al. PATENT OR DATE OF PATENT HOLDER OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 5,061,703 10/29/1991 Merz Pharma GmbH & Co. KGaA 2 8,039,009 B2 10/18/2011 Forest Laboratories Holdings, Ltd. 3 6,168,209 B2 5/1/2012 Adamas Pharmaceuticals, Inc. 4 8,173,708 B2 5/8/2012 Adamas Pharmaceuticals, Inc. 5 8,283,379 B2 10/9/2012 Adamas Pharmaceuticals, Inc. In the above—entitled case, the following patent(s)/ trademark(s) have been included: DATE INCLUDED INCLUDED BY Amendment Cross Bill Answer DATE OF PATENT PATENT OR HOLDER OF PATENT OR TRADEMARK TRADEMARK NO OR TRADEMARK in the above-entitled case, the following decision has been rendered or judgement issued: DECISION/JUDGEMENT

(BY) DEPUTY CLERK

DATE

CLERK

Copy 1—Upon initiation of action, mail this copy to Director—Copy 3—Upon termination of action, mail this copy to Director—Copy 2—Upon filing document adding patent(s), mail this copy to Director—Copy 4—Case file copy

ADDENDUM TO AO 120 (ADDITIONAL PATENTS)

DO	OCKET NO	DATE FILED	L.S. DISTRICT COURT
***************************************	APTOCOCO TECCHA	4/21/2014	For the District of Delaware
PL.	AINTIFT		DEFENDANT
FC	DREST LABORATOR	RIES, INC., et al.	AMNEAL PHARMACEUTICALS LLC, et al.
	PATENT OR TRADEMARK NO	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OF TRADEMARK
6	8,329,752 B2	12/11/2012	Adamas Pharmaceuticals, Inc.
7	8,362,085 B2	1/29/2013	Adamas Pharmaceuticals, Inc.
8	8,598,233 B2	12/3/2013	Adamas Pharmaceuticals, Inc.
ij			
10	- Control of the Cont		